This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
  • 00
  • 00
  • 00
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering



StemMedical is a Danish cell therapy biotech with 18 employees.
We have 2 focus areas:1) Femhealth (at commercial stage)2) Osteoarthritis (OA) (at pre-clinical stage)
Our Femhealth offerings focus on breast reconstruction and augmentation. Approx 40% of our patients presents with complications after plastic surgery (capsular contractions, breast implant illness, etc) and need to have their implants removed. Our technology (see product summary for description) allows the patients to avoid a collapsed breast following implant removal. In the next few years, we plan on also offering our products for post-mastectomy breast reconstruction. Our Femhealth products are launched in Denmark, and we have just (last week) obtained UK HTA approval and are thus poised for a UK launch this winter.
For OA, we have a lead candidate that will enter clinical phase 1 trial in 2024 (we just received regulatory approval for our phase 1 trial application this week) with a readout in 2025. Our ph1 trial will include 20 patients and will be conducted by Sanos (CRO) who is specialized in osteoarthritis of the knee which will be our lead OA indication.
Behind both our Femhealth offerings as well as our OA candidate is a proprietary IP protected mesenchymal stem cell manufacturing platform capable of producing large amounts of mesenchymal stem cells (MSCs). We are capable of producing an unprecedented 12-16 billion cells per patient per batch with enables high tissue graft survival in our breast reconstruction patients, and will hopefully demonstrate halting or reversal of disease progression in our OA ph1 trial.